Vaccine and diabetes drug to protect insulin-making cells
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests whether combining a shingles vaccine (Shingrix) with a diabetes medicine (semaglutide) can help preserve the body's ability to make insulin in people recently diagnosed with type 1 diabetes. It may slow the progression of the disease and reduce insulin needs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 50 years old.
- You must have been diagnosed with type 1 diabetes within the last 100 days.
- You must have started insulin treatment within the last 100 days.
- Your body must still be making some insulin (confirmed by a blood test).
- You must have at least one type 1 diabetes-related antibody (a sign of the autoimmune attack).
- You must be willing to use intensive insulin therapy and monitor your glucose regularly.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (rezpegaldesleukin) to see if it can help preserve the body's ability to make some insulin in people recently diagnosed with type 1 diabetes. It's for children and adults diagnosed within the past 100 days.
This trial tests a medication (called a GLP-1 receptor agonist) to see if it can help people in the earliest stage of type 1 diabetes keep their insulin-making cells working longer. It might help delay the need for insulin injections.
This trial tests if adding semaglutide and empagliflozin to your automated insulin delivery system (like a smart pump) can improve blood sugar control for adults with type 1 diabetes. It may help with both glucose levels and weight management.
This study tests whether a GLP-1 receptor agonist (a type of medicine that helps control blood sugar and appetite) can improve metabolic health in people with early type 1 diabetes. It may be an option if you have already taken teplizumab to delay the disease or were recently diagnosed with type 1 diabetes.
This study tests if starting two newer diabetes drugs (empagliflozin and semaglutide) soon after diagnosis, along with metformin, helps control blood sugar better than metformin alone. It's for people diagnosed with type 2 diabetes in the last two years who are already taking a high dose of metformin.
This trial tests whether adding a weekly semaglutide injection (a GLP-1 drug) to a closed-loop insulin system can help reduce the need for carb counting in people with type 1 diabetes. It aims to improve blood sugar control and make diabetes management easier.
Hear when a new Type 1 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.